Brief: Kala Pharmaceuticals Submits Investigational New Drug Application For Kpi-012 For Treatment Of Persistent Corneal Epithelial Defect

KALA BIO

28/11/2022 21:09

Nov 28 (Reuters) - Kala Pharmaceuticals Inc  KALA.O :
    * KALA PHARMACEUTICALS ANNOUNCES SUBMISSION OF
INVESTIGATIONAL NEW
DRUG APPLICATION FOR KPI-012 FOR THE TREATMENT OF PERSISTENT
CORNEAL EPITHELIAL DEFECT
    * CASH RUNWAY EXTENDED INTO 1Q 2025
    * ON-TRACK TO INITIATE PHASE 2B TRIAL IN 4Q 2022, WITH
TOPLINE
DATA EXPECTED IN 1Q 2024

Source text for Eikon:  ID:nGNXbX0zXf 
Further company coverage:  KALA.O 
 ((Reuters.Briefs@thomsonreuters.com
))